Skip to main content
OpenTrials
Completed

NCT Number: NCT01102205

Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease

Oxidative stress leads to or accompanies with numerous disease. Oxidative balance in subclinical hypothyroid or euthyroid state in Hashimoto disease are not known. Effect of levothyroxine therapy on oxidative balance are also not known in hashimoto disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–95 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Vakif Gureba Training and Research Hospital

Istanbul, 34100, Turkey (Türkiye)

About this study

oxidative stress markers will be measured initially(TAS,TOS,OSI,PARAOXONASE,ARYLESTERASA,PON1 PHENOTYPİNG,LİPİDPEROXİD).After 3 months therapy with levothyroxine measurements will be repeated except PON1 phenotyping.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age more than 18 years

Exclusion criteria

  • inability to give a written consent
  • other conditions and drug usage affect oxidative stress

Treatment and study plan

Primary outcomes

  1. Poxidative stress markers

    Time frame: After levotren therapy

Sponsors and collaborators

Lead sponsor

Vakif Gureba Training and Research Hospital

Other

Registry information

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Apr 13, 2010
Registry last updated
Jun 13, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.